Early research from the 2026 AAOS Annual Meeting indicates that GLP-1 medications like Ozempic and Wegovy may be associated with a higher relative risk of tendon ruptures. However, with an absolute risk increase of less than 1%, most patients remain unaffected. Discover the proposed mechanisms—from rapid activity increases to collagen signaling—and how to mitigate risk while continuing therapy.

A physician-written guide explaining who should avoid or use caution with GLP-1 and GLP-1/GIP weight-loss medications like semaglutide and tirzepatide.

Older adults enjoying the benefits of weight loss and eating healthy while using GLP-1 medications (semaglutide or tirzepatide) for safe weight loss, heart health, and muscle and bone support.